Sp1 inhibition-mediated upregulation of VEGF165b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549
Authors:
- 26 March 2011
- journal article
- Published by Springer Nature in Tumor Biology
- Vol. 32 (4) , 677-687
Abstract
Recombinant human endostatin (rh-endostatin), a potential antiangiogenic agent, is used in non-small cell lung carcinoma treatment and represses vascular endothelial cell growth factor (VEGF) levels in tumor cell. However, precise affection of rh-endostatin on the proangiogenic VEGF isoforms (VEGF165) or antiangiogenic VEGF isoforms (VEGF165b) is not clear. We therefore tested the hypothesis that rh-endostatin could alter expression of these isoforms to regulate tumor growth. A549 cells were exposed to rh-endostatin, and the expression of VEGF165 and VEGF165b was detected. The role of SP1 as a regulator of isoform expression was investigated. We then examined the anticancer and antiangiogenic efficacy of rh-endostatin in combination with exogenous VEGF165b against A549 cells, EA.HY 926 cells and xenograft model of human lung cancer. rh-Endostatin reduced VEGF165 and induced VEGF165b as well as inhibited SP1 in A549 cells. SP1 inhibitor (betulinic acid) also developed those changes. VEGF165b–rh-endostatin combination was highly synergistic and inhibited growth, survival, and migration of A549 cells, VEGF-mediated VEGFR2 phosphorylation in EA.HY 926 cells, and tumor growth in xenograft model of human lung cancer. rh-Endostatin downregulates proangiogenic vascular endothelial growth factor A (VEGFA) isoform and upregulates antiangiogenic VEGFA isoform, possibly through inhibition of SP1. Furthermore, VEGF165b sensitizes A549 to rh-endostatin treatment and enhances the anticancer effect of rh-endostatin.Keywords
This publication has 29 references indexed in Scilit:
- Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factorsJournal of Cell Science, 2008
- Recombinant human VEGF165b protein is an effective anti-cancer agent in miceEuropean Journal of Cancer, 2008
- Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cellsBritish Journal of Cancer, 2008
- The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in miceBritish Journal of Cancer, 2008
- VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapyBritish Journal of Cancer, 2008
- Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cellsBiochemical and Biophysical Research Communications, 2007
- Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanomaBritish Journal of Cancer, 2007
- The antitumoral effect of endostatin and angiostatin is associated with a down‐regulation of vascular endothelial growth factor expression in tumor cellsThe FASEB Journal, 2002
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990